All Stories

  1. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  2. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  3. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  4. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  5. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  6. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  7. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  8. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  9. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  10. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  11. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  12. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  13. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  14. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  15. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  16. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  17. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  18. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  19. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  20. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  21. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  22. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  23. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  24. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  25. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  26. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  27. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  28. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  29. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  30. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  31. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  32. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  33. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  34. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  35. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  36. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  37. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  38. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  39. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  40. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  41. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  42. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  43. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  44. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  45. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  46. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  47. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  48. A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
  49. Presentation, management, and outcomes of older compared to younger adults with hospital-acquired bloodstream infections in the intensive care unit: a multicenter cohort study
  50. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  51. A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).
  52. Examining global and gender disparities in high-impact evidence synthesis on lung cancer: A 2000-2024 analysis of Cochrane Library.
  53. Impact of race and ethnicity on financial toxicity in patients with genitourinary cancers.
  54. Burden of disease scenarios for 204 countries
  55. MP08-17 OUTCOMES OF INVASIVE PRIMARY URETHRAL CANCER IN WOMEN (IPUC): AN ANALYSIS FROM THE NATIONAL CANCER DATABASE
  56. Correction: The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
  57. 151 Exceptional Responders to Base Excision Repair (BER) Inhibition for Recurrent Glioblastoma Display Enrichment for DNA Damage Response Pathways: RNA Sequencing Analysis From a Multicenter Trial
  58. 501 Systemic Immunological Suppression in Glioblastoma Is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) From a Randomized Controlled Trial
  59. Safety and Feasibility of JAK Inhibitor Ruxolitinib in Newly-Diagnosed High-Grade Gliomas (CRUX): Final Trial Report
  60. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma
  61. The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
  62. Disparities in Noninvasive Traditional and Advanced Testing for Coronary Artery Disease: Findings from the INCAPS-COVID 2 Study
  63. Outcomes of invasive primary urethral cancer in women: An analysis from the national cancer database
  64. Treatment strategies and survival outcomes in Non-invasive Primary Urethral Cancer (NPUC): A comprehensive analysis from a large database
  65. “Open-window” craniectomy for the removal of frontal sinus mucosa to prevent a delayed mucocele: illustrative case
  66. Symptomatic Cerebellar Ptosis following Cerebellar Hematoma Evacuation: A Case Report and Review of the Literature
  67. Treatment Strategies for Primary Cavernous Sinus Meningiomas: A Systematic Review and Meta-analysis
  68. Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial
  69. Financial barriers and inequity in medical education in India: challenges to training a diverse and representative healthcare workforce
  70. Impact of tissue-agnostic approvals on management of primary brain tumors
  71. An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
  72. Management of Brain Metastases: A Review of Novel Therapies
  73. SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm
  74. Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries
  75. CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
  76. CTNI-21. PHASE I STUDY OF BTK INHIBITOR IBRUTINIB WITH TEMOZOLOMIDE AND RADIATION IN NEWLY-DIAGNOSED GLIOBLASTOMA (EQUILIBRIUM): FINAL TRIAL REPORT
  77. CTNI-55. A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  78. DNAR-05. EXCEPTIONAL RESPONDERS TO BASE EXCISION REPAIR (BER) INHIBITION FOR RECURRENT GLIOBLASTOMA DISPLAY ENRICHMENT FOR DNA DAMAGE RESPONSE PATHWAYS: RNA SEQUENCING ANALYSIS FROM A MULTICENTER TRIAL
  79. IMMU-02. IS DUAL AGENT IMMUNOTHERAPY SHIFTING THE EPIDEMIOLOGY OF MELANOMA BRAIN METASTASES? A REAL-WORLD ANALYSIS AND SINGLE-INSTITUTION VALIDATION
  80. IMMU-34. SYSTEMIC IMMUNE SUPPRESSION IN GLIOBLASTOMA IS TARGETED BY CONCURRENT VEGF AND PD-1 INHIBITION IN A DOSE-DEPENDENT MANNER: TRANSCRIPTOMIC FINDINGS THROUGH CITE-SEQ FROM A RANDOMIZED CONTROLLED TRIAL
  81. RTID-01. A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)
  82. SURG-27. 17-YEAR EXPERIENCE OF SURGICAL MANAGEMENT OF INTRADURAL EXTRAMEDULLARY (IDEM) TUMORS: CLINICAL OUTCOMES FROM A LOW- AND MIDDLE-INCOME COUNTRY
  83. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients
  84. Management of Postoperative Discitis with Debridement and Novel Technique of Local Antibiotic Instillation: Functional Outcomes from a Resource-Limited Setting
  85. Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
  86. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
  87. P03.15.B SURGICALLY TARGETED RADIATION THERAPY (START) FOR RECURRENT GLIOBLASTOMA: INITIAL OUTCOMES FROM A PROSPECTIVE MULTICENTER REGISTRY
  88. P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
  89. P07.13.B A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)
  90. P14.11.B A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  91. JS06.5.A TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
  92. Neurosurgeon’s Ode to Meningiomas
  93. Authors' Response to Letter Regarding ‘The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators’ (Preprint)
  94. Authors' Reply to: Research Training For Medical Students To Stand Out In Residency Applications. Comment on "The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and ...
  95. Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
  96. Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.
  97. Enhancing lung cancer screening through ‘Saved by the Scan’: Lessons from a multipronged public service advertising program.
  98. Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).
  99. Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.
  100. Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
  101. Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis.
  102. Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder.
  103. Ethnic disparities in biomarker testing and targeted therapy use in metastatic lung adenocarcinoma: A 2014-2021 analysis.
  104. Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.
  105. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
  106. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
  107. Authorship Diversity in Urology: 1998-2022 Cochrane Review Analysis
  108. Diploic Bone Channel Drilling Facilitates Dissection of the Midline Dura and Protects the Superior Sagittal Sinus in Hyperostosis Frontalis Interna
  109. SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM)
  110. DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
  111. Who coauthors Cochrane Reviews related to genitourinary cancers? A 1998-2022 analysis of country and gender diversity.
  112. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study
  113. Treatments for intracranial hypertension in acute brain-injured patients: grading, timing, and association with outcome. Data from the SYNAPSE-ICU study
  114. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators
  115. Monitoring committees in clinical trials
  116. Phases of clinical trials
  117. Correlation
  118. List of contributors
  119. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Case-Control Study
  120. Novel Therapeutic Approaches in Neoplastic Meningitis
  121. Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis
  122. Inequities in Country- and Gender-Based Authorship Representation in Cardiology-Related Cochrane Reviews
  123. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Case-Control Study (Preprint)
  124. The Future of Pulmonary Medicine Physician Work-Force in India
  125. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries
  126. Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
  127. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis
  128. COVID-19-Associated Mucormycosis in a Tertiary Care Hospital in India: A Case Series
  129. Intracranial Pressure Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
  130. Authorship Diversity in Cochrane Systematic Reviews of Stroke: Inequities in Global Representation (P18-2.002)
  131. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
  132. Rising Inequity and Disparities in Medical Education in India: Challenges to Training a Representative Workforce (Preprint)
  133. Advanced subspecialty cardiology training in India in 2022: challenges and future directions
  134. Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study
  135. COUNTRY AND GENDER DIVERSITY IN CARDIOLOGY-RELATED COCHRANE REVIEWS: INEQUITIES IN GLOBAL REPRESENTATION
  136. Total hip arthroplasty for failed osteosynthesis of proximal femoral fractures: Clinical outcomes from a low- and middle-income country
  137. Overseas Medical Students in Ukraine and War-Related Interruption in Education: Global Health Considerations from India
  138. Management of postoperative discitis with debridement and local antibiotic infusion: functional outcomes from a low-middle-income country
  139. Functional outcomes after modified Blair's procedure for ankle arthritis secondary to Hawkins type III talus injuries: A retrospective cohort study
  140. In Reply: Predictors of Academic Neurosurgical Career Trajectory Among International Medical Graduates Training Within the United States
  141. The perceived impact of the Covid-19 pandemic on medical student education and training – an international survey
  142. Educating the Next Generation of Global Neurosurgeons: Competencies, Skills, and Resources for Medical Students Interested in Global Neurosurgery
  143. Percutaneous image-guided cryoablation of spinal metastases: A systematic review
  144. Pediatric Brain Tumors: From Modern Classification System to Current Principles of Management
  145. BJS commission on surgery and perioperative care post-COVID-19
  146. Comparison of Blister Aneurysm Treatment Techniques: A Systematic Review and Meta-Analysis
  147. Impact of COVID-19 on Diagnostic Cardiac Procedural Volume in Oceania: The IAEA Non-Invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
  148. Learning to practice medicine during COVID-19 and mucormycosis epidemics: an intern perspective from India
  149. Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
  150. Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World
  151. Lessons from the life of Asia’s first female neurosurgeon for modern neurosurgical trainees and educators worldwide
  152. MP67-14 SCIENTIFIC AUTHORSHIP OF COCHRANE SYSTEMATIC REVIEWS IN UROLOGY: A 2020 ANALYSIS
  153. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia
  154. State of Accredited Endovascular Neurosurgery Training in India in 2021: Challenges to Capacity Building in Subspecialty Neurosurgical Care
  155. The Perceived Impact of the Covid-19 Pandemic on Medical Student Education and Training – An International Survey
  156. SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
  157. Letter: Predictors of Academic Neurosurgical Career Trajectory Among International Medical Graduates Training Within the United States
  158. Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
  159. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe
  160. Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!
  161. Anxiety, Uncertainty, and Resilience of Medical Students Worldwide during the COVID-19 Pandemic
  162. Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study
  163. Abstract 831: State of medical and surgical oncology training in India: An infrastructural challenge to delivering high-quality cancer care
  164. Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study
  165. Global Landscape of Glioblastoma Multiforme Management in the Stupp Protocol Era: Systematic Review Protocol
  166. Letter to the Editor Regarding “Characterizing the Effect of Pass/Fail U.S. Medical Licensing Examination Step 1 Scoring in Neurosurgery: Program Directors' Perspectives”
  167. The perceived global impact of the COVID‐19 pandemic on doctors’ medical and surgical training: An international survey
  168. Antibiotics for treatment of irritable bowel syndrome in adults
  169. Medical Students in Global Neurosurgery: Rationale and Role
  170. Retractions and Withdrawals in Neurology Literature: A 2020 Analysis of the Retraction Watch Database (2668)
  171. The perceived global impact of the COVID-19 pandemic on doctors’ medical and surgical training: an international survey
  172. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study
  173. Timing of surgery following SARS-CoV-2 infection
  174. Biographies of international women leaders in neurosurgery
  175. Decline of Empathy During Medical Education
  176. Decline of Empathy During Medical Education
  177. Delivering High-Quality, Equitable Care in India: An Ethically-Resilient Framework for Healthcare Innovation After COVID-19
  178. Letter by Ozair et al Regarding Article, “The Upcoming Epidemic of Heart Failure in South Asia”
  179. International Impact of COVID-19 on the Diagnosis of Heart Disease
  180. SARS-CoV-2 Vaccination in India: Considerations of Hesitancy and Bioethics in Global Health
  181. Large Cerebral Infarction in Tuberculous Meningitis: Case Report of an Uncommon Complication
  182. Scrub Typhus Presenting with Hemiparesis: Case Report of a Rare Manifestation
  183. 0.54111/0001/vv16
  184. Adherence to Lockdown and Social-Distancing Policies Amidst COVID-19 Pandemic: A Behavioral and Socio-Economic Perspective from India
  185. Letter to the Editor Regarding “Strategies to Address Projected Challenges Facing Foreign Applicants in the U.S. Neurosurgery Match”
  186. ACUTE FATTY LIVER OF PREGNANCY PRESENTING AS INTRAUTERINE FETAL DEATH, POSTPARTUM HEMORRHAGE AND MULTI-ORGAN FAILURE: NEED FOR A MULTI-DISCIPLINARY, INTENSIVIST-LED MANAGEMENT
  187. Learning high‐value care in developing countries
  188. Why are India’s Best Medical Graduates not Preferring ENT for Postgraduate Training Through NEET-PG?
  189. Abstracts from the International Science Symposium on HIV and Infectious Diseases (ISSHID 2019): Infectious diseases
  190. Scrub Typhus: Case of a Rare Etiology Behind Intracerebral Hemorrhage (204)
  191. Stroke in persons with disability
  192. Postoperative urinary retention: A controlled trial of fixed-dose spinal anesthesia using bupivacaine versus ropivacaine
  193. Transhepatic intraperitoneally migrated biliary stent: A rare finding during laparoscopic cholecystectomy
  194. Training and Delivery of Critical Care Medicine in India: Concerns Revealed by COVID-19 Pandemic
  195. A rare etiology behind isolated lateral rectus palsy: Scrub typhus
  196. Scrub typhus manifesting with intracerebral hemorrhage: Case report and review of literature
  197. Impaled roadside guardrail in the neck: Case of a failed motorcycle stunt
  198. Academic quality of incoming ophthalmology residents in India: Concerns for the future
  199. Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the dual challenge of psychosocial issues and an uncommon medical condition
  200. Upsurge of chikungunya cases in Uttar Pradesh, India
  201. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators
  202. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators